[
  {
    "ts": null,
    "headline": "Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimer’s, Study Shows. What It Means for the Stocks.",
    "summary": "Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimer’s, Study Shows. What It Means for the Stocks.",
    "url": "https://finnhub.io/api/news?id=5d34a1e430ec5cf462b5066b308b6b07863b41a2039e90394ab8ad224cf9d0c4",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737459540,
      "headline": "Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimer’s, Study Shows. What It Means for the Stocks.",
      "id": 132458822,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimer’s, Study Shows. What It Means for the Stocks.",
      "url": "https://finnhub.io/api/news?id=5d34a1e430ec5cf462b5066b308b6b07863b41a2039e90394ab8ad224cf9d0c4"
    }
  },
  {
    "ts": null,
    "headline": "Overvaluation And Record Highs: Why The Bull Market Might Still Have Room To Run",
    "summary": "The stock marketâs brief downturn appears to be ending. Learn more about many high-quality blue-chip bargains that remain available.",
    "url": "https://finnhub.io/api/news?id=e77e88b101eb5e67d7421f9d90a4827f92457674eb4c75ea97abed6d231b8421",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737442800,
      "headline": "Overvaluation And Record Highs: Why The Bull Market Might Still Have Room To Run",
      "id": 132435475,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1291620275/image_1291620275.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The stock marketâs brief downturn appears to be ending. Learn more about many high-quality blue-chip bargains that remain available.",
      "url": "https://finnhub.io/api/news?id=e77e88b101eb5e67d7421f9d90a4827f92457674eb4c75ea97abed6d231b8421"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Market Overreacted",
    "summary": "Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas. See why LLY stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=f7cdd8e327108d81abd628c532e2840f2ab5c21a7d8cd9ab4282b61b3eec1ee7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737437923,
      "headline": "Eli Lilly: Market Overreacted",
      "id": 132435094,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1289941019/image_1289941019.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas. See why LLY stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=f7cdd8e327108d81abd628c532e2840f2ab5c21a7d8cd9ab4282b61b3eec1ee7"
    }
  }
]